Next Article in Journal
Characterizing the Interaction between the HTLV-1 Transactivator Tax-1 with Transcription Elongation Factor ELL2 and Its Impact on Viral Transactivation
Previous Article in Journal
Three Component Composite Scaffolds Based on PCL, Hydroxyapatite, and L-Lysine Obtained in TIPS-SL: Bioactive Material for Bone Tissue Engineering
Previous Article in Special Issue
Evaluating Molecular Docking Software for Small Molecule Binding to G-Quadruplex DNA
Communication

Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells

1
Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Hospital del Mar Medical Research Institute (IMIM), Pompeu Fabra University (UPF), 08003 Barcelona, Spain
2
InterAx Biotech AG, PARK InnovAARE, 5234 Villigen, Switzerland
3
Infectious Diseases Department, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Barcelona Hospital Campus, Vall d’Hebron Hospital Universitari, 08035 Barcelona, Spain
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Giulio Vistoli
Int. J. Mol. Sci. 2021, 22(24), 13592; https://doi.org/10.3390/ijms222413592
Received: 1 December 2021 / Revised: 13 December 2021 / Accepted: 15 December 2021 / Published: 18 December 2021
(This article belongs to the Special Issue New Avenues in Molecular Docking for Drug Design 2021)
Since the start of the COVID-19 outbreak, pharmaceutical companies and research groups have focused on the development of vaccines and antiviral drugs against SARS-CoV-2. Here, we apply a drug repurposing strategy to identify drug candidates that are able to block the entrance of the virus into human cells. By combining virtual screening with in vitro pseudovirus assays and antiviral assays in Human Lung Tissue (HLT) cells, we identify entrectinib as a potential antiviral drug. View Full-Text
Keywords: SARS-CoV-2; COVID-19; drug repurposing; virtual screening; viral cell entry assays SARS-CoV-2; COVID-19; drug repurposing; virtual screening; viral cell entry assays
Show Figures

Figure 1

MDPI and ACS Style

Peralta-Garcia, A.; Torrens-Fontanals, M.; Stepniewski, T.M.; Grau-Expósito, J.; Perea, D.; Ayinampudi, V.; Waldhoer, M.; Zimmermann, M.; Buzón, M.J.; Genescà, M.; Selent, J. Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells. Int. J. Mol. Sci. 2021, 22, 13592. https://doi.org/10.3390/ijms222413592

AMA Style

Peralta-Garcia A, Torrens-Fontanals M, Stepniewski TM, Grau-Expósito J, Perea D, Ayinampudi V, Waldhoer M, Zimmermann M, Buzón MJ, Genescà M, Selent J. Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells. International Journal of Molecular Sciences. 2021; 22(24):13592. https://doi.org/10.3390/ijms222413592

Chicago/Turabian Style

Peralta-Garcia, Alejandro, Mariona Torrens-Fontanals, Tomasz M. Stepniewski, Judith Grau-Expósito, David Perea, Vikram Ayinampudi, Maria Waldhoer, Mirjam Zimmermann, María J. Buzón, Meritxell Genescà, and Jana Selent. 2021. "Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells" International Journal of Molecular Sciences 22, no. 24: 13592. https://doi.org/10.3390/ijms222413592

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop